Pharmaknowl’s Participation at DIA Singapore Annual Meeting 2026

PharmaKnowl Consulting is pleased to announce our participation as an exhibitor and speaker at the DIA Singapore Annual Meeting 2026, taking place on 16–17 September 2026 at the One Farrer Hotel, Singapore.

Held under the theme “Sustainable Innovation for Tomorrow – Advancing Regulatory and Clinical Frontiers to Accelerate Patient Access in Asia,” the DIA Singapore Annual Meeting 2026 brings together regulators, industry leaders, academia, and clinical experts from across the region to explore the developments shaping the future of healthcare in Asia. Discussions will center on regulatory convergence and reliance pathways across APAC and ASEAN, modern clinical trial modalities (RWD/RWE, DCT, IVD/MD, and innovative endpoints), AI and digital transformation in regulatory affairs, and next-generation, technology-enabled clinical operations.

Mohammed Jobran, CEO of PharmaKnowl Consulting, will be speaking on Day 1, 16 September, from 1:20 PM – 1:40 PM SGT, presenting on: “Innovation in Medicines Regulation: SFDA Accelerated Pathways by Development Stage”

This session will offer participants a closer look at how the Saudi Food and Drug Authority (SFDA) is accelerating access to innovative medicines through structured, stage-based regulatory pathways and what this means for companies planning their regulatory strategy for the Saudi and broader GCC markets.

As an SFDA-licensed regulatory consulting firm based in Saudi Arabia, PharmaKnowl Consulting supports pharmaceutical and biotechnology companies in navigating the full regulatory lifecycle from product registration and lifecycle management to pharmacovigilance and market access across Saudi Arabia and the wider Middle East region. Our team works closely with global organizations to ensure regulatory strategies remainefficient, compliant, and aligned with SFDA and international requirements.

During the meeting, our experts will be available to discuss how PharmaKnowl can support your organization with:

• SFDA regulatory strategy and submissions, including new product registration, variations, and accelerated approval pathways aligned to product development stage.

• Pharmacovigilance solutions, including Local QPPV services, Pharmacovigilance System Master File (PSMF) preparation and maintenance, ICSR processing, signal detection, and Risk Management Plans (RMPs).

• Market access and lifecycle management for companies entering or expanding within the Saudi and GCC pharmaceutical markets.

• Regulatory intelligence and compliance support, helping organizations stay ahead of evolving SFDA requirements and regional harmonization efforts across APAC, the Middle East, and beyond.

Whether you are preparing to enter the Saudi market, exploring accelerated regulatory pathways, or looking for a trusted regulatory and pharmacovigilance partner in the region, our specialists are ready to discuss practical solutions tailored to your organization’s needs.

👉 Scan the QR code to schedule a meeting with our team at DIA Singapore Annual Meeting 2026 or catch Mohammed Jobran’s session on 16 September to learn more about how SFDA’s accelerated pathways can support your regulatory strategy in Saudi Arabia.